Future investigations should integrate multidimensional pruritus profiling with biomarker stratification (e.g., serum IL-31 levels) to differentiate methodological artifacts (“noise”) from genuine pathophysiological signals in safety outcome assessments. This evidence concerns the gene IL31 and Pruritus.